A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non pharmaceutical-grade) cannabidiol (CBD) to Epidiolex for treatment of seizures. The main questions it aims to answer are: * How well does a gradual switch from 'artisanal' CBD to Epidiolex work? * Does the same dose of Epidiolex as 'artisanal' CBD work best? * What side-effects or medical problems do participants have when switching from 'artisanal' CBD to Epidiolex? Researchers will examine how successful switching from 'artisanal' CBD to Epidiolex is. Participants will: * Gradually increase their dose of Epidiolex and reduce their dose of 'artisanal' CBD until they are taking just Epidiolex * Visit the clinic five times over 20 weeks for checkups and tests * Keep a diary of their seizures, symptoms and the number of times they use a rescue seizure medication

NCT Number	NCT06924827
Lead Sponsor	Elizabeth Donner Collaborators: Jazz Pharmaceuticals, Alberta Children's Hospital, BC Children's Hospital Research Institute
Conditions	Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
Enrollment	25 participants
Start Date	2026-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-17